A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks
 in patients with chronic hepatitis C genotype 1 infection.
Inclusion Criteria:

 -  The patient must be 18 to 65 years of age, inclusive.

 -  Primary diagnosis of chronic HCV infection.

 Exclusion Criteria:

 -  Patients who did not respond or relapsed following therapy with interferon.